Blockage of PD-L1/PD-1 pathway for enhancing the chemotherapeutic efficacy of cisplatin / 实用医学杂志
The Journal of Practical Medicine
; (24): 47-50, 2016.
Article
в Zh
| WPRIM
| ID: wpr-487915
Ответственная библиотека:
WPRO
ABSTRACT
Objective To explore the anti-tumor effect and the influence of antitumor immunity of PD-L1/PD-1 blocked by PD-1 antibody combined with cisplatin. Methods Tumor models were established by injecting TC-1 cells into C57BL/6 mice, and the mice were divided into four groups (n = 4). The tumor growth curves and survival curves were drawn to observe the anti-tumor effect. The tumors were then removed; and the PD-L1 and CD8+ T cells were analyzed by immunohistochemical method. Results The anti-tumor effect was greater in the cisplatin group , PD-1 antibody group , and PD-1 antibody plus cisplatin group than in the control group (P < 0.05). Expression of PD-L1 in the tumor tissues was markedly increased in the cisplatin group and it was obviously decreased in the combination group (P < 0.05). CD8+ T cells decreased in the cisplatin group; and expression of CD8+ T cells was significantly increased the combination group (P < 0.05). Conclusion The anti-tumor effect and anti-tumor immunity of cisplatin are enhanced by blocking PD-L1/PD-1 pathway with PD-1 antibody.
Полный текст:
1
База данных:
WPRIM
Язык:
Zh
Журнал:
The Journal of Practical Medicine
Год:
2016
Тип:
Article